SOFIA FLOUDA

MD, Msc, cPhD
Resident Doctor
Rheumatology
Attikon University Hospital

[The Lancet Rheumatology @TheLancetRheum]

NEW REVIEW—Identification of red flags for IgG4-related disease: an international @ern_reconnet framework https://t.co/RWon1HZxVB
Free to read with registration on https://t.co/28wkm5ab69

[SOFIA FLOUDA @SFlouda]

Excellent work!!!
https://t.co/XuohmhsoaT

[Annals of the Rheumatic Diseases @eular_ARD]

In the Sept issue ▶️ #APS #SLE by #transcriptomeanalysis 🦋
❇️ #IFN I-II signature ▶️ highest in SLE-aPL-negative
🔵 Venous ▶️ neutrophils & B cells
🔴 Arterial ▶️ DNA-damage-response & impaired metabolism
🔗 https://t.co/vPVv6gcGLg
@DionysisNik @george_bertsias @IoannisParodis

[Annals of the Rheumatic Diseases @eular_ARD]

Treatment algorithms for the treatment of Behcet’s disease according to organ involvement (Part 2)

Pr. Gulen Hatemi
#EULAR2023
NZ

[Annals of the Rheumatic Diseases @eular_ARD]

2023 SLE Recommendations

🔹Lower GC dose (5 mg instead of 7.5)
🔹 Early use of biologics for corticosparing
🔹 Cyclophosphamide if life-threatening
🔹 MMF: new in hemato manif
🔹Lupus nephritis: VCL vs BEL???
🔹Maintain trt for 3 years then taper, except HCQ

#EULAR2023
NZ

[Lupus Europe @LupusEurope]

Take home messages.

Most important changes, according to Dimitrios Boumpas:

♦️ Threshold in GC below 5mg/day and try to avoid them completely

♦️ Possibility of using biologics as fist line in order to ⬇️ GC and achieve early remission or low disease activity.

#EULAR2023

[Lupus Europe @LupusEurope]

Active lupus nephritis:
♦️IV-CY or MMF & GC as inicial therapy. Combination therapy with BEL/CNIs should be considered
♦️BEL may be used at the beginning- good evidence
♦️Belimumab & VCS should be considered in all patients
♦️ No distinction in class III/IV & V
#EULAR2023

[Lupus Europe @LupusEurope]

“We need new treatments to be able to ⬇️ steroids” - Dimitrios Boumpas

#EULAR2023

[Lupus Europe @LupusEurope]

Key points from Dimitrios Boumpas’ session about how to treat #lupus.

#EULAR2023